{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:24:13Z","timestamp":1777501453967,"version":"3.51.4"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jcp.0b013e3181ee84c7","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T12:13:40Z","timestamp":1283429620000},"page":"504-511","source":"Crossref","is-referenced-by-count":62,"title":["Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers"],"prefix":"10.1097","volume":"30","author":[{"given":"Jes\u00fas","family":"Novalbos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gallego-Sand\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.","volume":"244","author":"Jansen","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0447.1992.tb01473.x","article-title":"Risperidone versus haloperidol in the treatment of chromic schizophrenia inpatients: multicenter double-blind comparative study.","volume":"85","author":"Claus","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"R3-4-20210128","first-page":"25","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients published correction appears in J Clin Psychopharmacol 1993;13:149.","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans.","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxy-risperidone by human cytochromes P450 2D6 and 3A4.","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.","volume":"54","author":"Huang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/cbf.1258","article-title":"Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population.","volume":"24","author":"Menoyo","year":"2006","journal-title":"Cell Biochem Funct"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/clinchem\/48.9.1412","article-title":"Rapid and reliable method for cytochrome P450 2D6 genotyping.","volume":"48","author":"Stamer","year":"2002","journal-title":"Clin Chem"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-9236(95)90151-5","article-title":"Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.","volume":"57","author":"Agundez","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00008571-199910000-00013","article-title":"Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.","volume":"9","author":"Bernal","year":"1999","journal-title":"Pharmacogenetics"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","article-title":"Serum concentrations and side effects in psychiatric patients during risperidone therapy.","volume":"20","author":"Olesen","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s002280100372","article-title":"Risperidone metabolism in relation to CYP2D610 allele in Korean schizophrenic patients.","volume":"57","author":"Roh","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","article-title":"Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.","volume":"25","author":"Mihara","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.","volume":"114","author":"van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v60n0709","article-title":"A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.","volume":"60","author":"Bork","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-2002-31517","article-title":"Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.","volume":"35","author":"Kohnke","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse reactions and discontinuation.","volume":"66","author":"De Leon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007691-200106000-00007","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.","volume":"23","author":"Spina","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","article-title":"Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.","volume":"22","author":"Spina","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4088\/JCP.v61n0810b","article-title":"Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer.","volume":"61","author":"Guzey","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/01.jcp.0000145347.68664.4e","article-title":"High dose of depot risperidone in a nonresponder schizophrenic patient.","volume":"24","author":"Albrecht","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/j.1875-9114.1997.tb03071.x","article-title":"Risperidone: effects of formulations on oral bioavailability.","volume":"17","author":"Gutierrez","year":"1997","journal-title":"Pharmacotherapy"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/009127009903900314","article-title":"Effect of venlafaxine on the pharmacokinetics of risperidone.","volume":"39","author":"Amchin","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00279094","article-title":"A routine method for the establishment of permanent growing lymphoblastoid cell lines.","volume":"73","author":"Neitzel","year":"1986","journal-title":"Hum Genet"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0009-9236(96)90148-4","article-title":"The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.","volume":"60","author":"Chen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0140-6736(90)92086-W","article-title":"Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification.","volume":"336","author":"Heim","year":"1990","journal-title":"Lancet"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00008571-199306000-00001","article-title":"Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.","volume":"3","author":"Broly","year":"1993","journal-title":"Pharmacogenetics"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0014-5793(96)00779-X","article-title":"Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.","volume":"392","author":"Lovlie","year":"1996","journal-title":"FEBS Lett"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":"Detection of the poor metabolizer associated CYP2D6 (D) gene deletion allele by long-PCR technology.","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF02969428","article-title":"Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.","volume":"29","author":"Cho","year":"2006","journal-title":"Arch Pharm Res"},{"key":"R35-4-20210128","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.","volume":"29","author":"Yasui-Furukori","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0091270002239819","article-title":"Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.","volume":"43","author":"Yasui-Furukori","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clpt.2005.03.009","article-title":"Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.","volume":"78","author":"Nakagami","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00004714-200102000-00020","article-title":"Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.","volume":"21","author":"Spina","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v58n1010b","article-title":"Risperidone and cytochrome P450 3A.","volume":"58","author":"de Leon","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JCP.0b013e3181a289e0","article-title":"Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.","volume":"29","author":"Kang","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","article-title":"Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.","volume":"29","author":"Hendset","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R42-4-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02246302","article-title":"A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquine and risperidone.","volume":"119","author":"Nyberg","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.","volume":"21","author":"Melkersson","year":"2006","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","article-title":"Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.","volume":"27","author":"Troost","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psyneuen.2007.10.010","article-title":"Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.","volume":"33","author":"Duval","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.","volume":"21","author":"Wang","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.2008.234","article-title":"An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.","volume":"85","author":"Friberg","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-3565(25)10814-8","article-title":"Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.","volume":"262","author":"Bowden","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.pnpbp.2007.10.019","article-title":"The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone.","volume":"32","author":"Al Hadithy","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/tpj.2009.26","article-title":"A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.","volume":"9","author":"Gasso","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881104042618","article-title":"QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.","volume":"18","author":"Llerena","year":"2004","journal-title":"J Psychopharmacol"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.tpj.6500160","article-title":"Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.","volume":"3","author":"Desai","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci"},{"key":"R56-4-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/taap.2002.9383","article-title":"In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.","volume":"180","author":"Titier","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"R57-4-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00213-001-0933-x","article-title":"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.","volume":"159","author":"Aravagiri","year":"2002","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201010000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T13:16:44Z","timestamp":1740489404000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201010000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181ee84c7","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}